Trial
NCT01705483
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Pharmacokinetics of ASP9853
Intervention
ASP9853
Why stopped
Based on the results of the Phase 1 data, the company decided not to pursue the development of this drug at this time.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-07